Sapio HealthSapio Health
  • Today
  • Patients
  • Inbox
  • Calendar
Insight
  • Population
  • Quality (QOF)
System
  • Models
  • Data feeds
  • Settings
Practice trajectory
-26%
JD
Dr John Dolittle
Ashford Vale Medical Group
Patients/Greta Larsen · SH-10384
← Practice Horizon

Greta Larsen

59F · SH-10384OFF
Cancer survivor + cardiometabolic drift · Graphic designer
Next consult
No scheduled consult
Gray zone· p 0.61Trending worse
Trajectory headline
Post-anthracycline surveillance should be active. No echo since 2022; LDL + BP trending. Invite for focused review.
Model priority
Gray zone · pattern emerging
Biggest single change you could makeLifestyle programme → −34% (Triglycerides)
Patient Context Card · AIME

Brief

Trajectory-grounded orientation for today's appointment.

Survivorship pathway has slipped. Model flags her back into active surveillance.

Trajectory narrative

Greta completed breast-cancer treatment in 2020 (anthracycline-based chemo + 5y tamoxifen). Oncology follow-up discharged her last year. Cardiometabolic drift has been slow but steady — blood pressure and lipids have nudged upward, BMI is stable but weight redistribution is visible. Her survivorship pathway calls for an echo and active CV surveillance.

Active concerns
  • Anthracycline cumulative exposure — 240 mg/m²
  • No echo since 2022
  • LDL 3.6; BP 138/86 at last review
  • 218 days since last GP consult
Suggested consultation focus
  • Invite for cardio-oncology surveillance review
  • Order echo + NT-proBNP + lipids
  • Consider statin initiation post-review
Supporting record context
Current medications
Nil (tamoxifen completed 2024)
Allergies
NKDA
Oncology
Stage II ER+ breast ca (2019); AC-T + RT; 5y tamoxifen completed 2024
For demonstration purposes. Not a diagnostic tool.
Horizon-1 · Syndrome activation

Latent clinical states

Output of the dynamic hypergraph. Direction = trajectory on that axis.

Cardio-oncology
0.58
Metabolic (mild)
0.45
For demonstration purposes. Not a diagnostic tool.